InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

InflaRx N.V.

An announcement from InflaRx ( ($IFRX) ) is now available. On April 2, 2026, InflaRx N.V. announced it had convened its 2026 annual general meeting...

InflaRx Sets April 23, 2026 AGM to Approve 2025 Accounts, Board Mandates and New LTIP

The latest announcement is out from iFOREX Financial Trading Holdings Ltd ( ($GB:IFRX) ). iFOREX Financial Trading Holdings Ltd. has admitted 296,8...

iFOREX Admits New Shares to LSE and Updates Total Voting Rights

Analysts have been eager to weigh in on the Healthcare sector with new ratings on InflaRx (IFRX) and Kuros Biosciences (CSBTF). InflaRx (IFRX) Life...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: InflaRx (IFRX) and Kuros Biosciences (OtherCSBTF)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on InflaRx (IFRX) and Sarepta Therapeutics (SRPT) with ...

Analysts Offer Insights on Healthcare Companies: InflaRx (IFRX) and Sarepta Therapeutics (SRPT)

iFOREX Financial Trading Holdings Ltd ( ($GB:IFRX) ) has issued an announcement. iFOREX Financial Trading Holdings has issued and allotted 296,800 ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IFRX	$0.97	0.00%	1.15M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IFRX	$0.97	0%	1.15M
3
4
5
6

IFRX

IFRX

No Data Available

Get InflaRx N.V. Data in Excel

Get InflaRx N.V. Data in Excel